Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183526 | 0.82 | KMT2A (0.50) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL4181537 | 0.79 | KMT2A (0.61) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL4182162 | 0.77 | KMT2A (0.77) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL10633295 | 0.76 | TRPV4 (0.50) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL4184689 | 0.74 | KMT2A (0.55) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL7420609 | 0.73 | HTT (0.78) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL4183508 | 0.73 | KMT2A (0.53) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL4194203 | 0.72 | KMT2A (0.59) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL5169194 | 0.72 | KMT2A (0.69) | KMT2AHTTLMNAMAPK1PDE4A | |
| SCHEMBL10633354 | 0.71 | KMT2A (0.48) | KMT2AHTTLMNAMAPK1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | KMT2A 3729/4885HTT 935/4885LMNA 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.